New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:12 EDTTNXPTonix Pharmaceuticals appoints Sullivan Chief Medical Officer
Tonix Pharmaceuticals has appointed Gregory Sullivan Chief Medical Officer, a newly created position. He will oversee medical aspects of the company's clinical research and development program, which is focused on common disorders of the central nervous system. Sullivan brings to Tonix more than two decades of experience in the diagnosis, treatment and neurobiology of anxiety and mood disorders. Sullivan has served on the company's Scientific Advisory Board since 2010 and additionally has been a consultant to the company since 2013.
News For TNXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2015
08:44 EDTTNXPTonix Pharmaceuticals presents additional data on Tonmya
Tonix Pharmaceuticals presents additional results from its completed 12-week, 205-patient Phase 2b BESTFIT clinical study of Tonmya for the treatment of fibromyalgia. Tonmya is designed for chronic daily use at bedtime to treat fibromyalgia. Of the 174 patients who completed the BESTFIT study, 172 were evaluable for the analyses described in this paragraph. Of these 172, 88 patients were treated with Tonmya, and 84 were treated with placebo. According to a tertile analysis of reported sleep quality improvement, the 54 of these 172 patients who reported the greatest improvement in sleep quality, or top sleep tertile, were examined in further detail. Of those in the Tonmya group, 36, or 41%, were in the top sleep tertile compared to 18 of the 84 patients, or 21%, in the placebo group. Of the 42 patients in the top sleep tertile who experienced at least a 30% improvement in their pain from baseline, 28, or 67%, had received Tonmya, compared to 14, or 33%, who had received placebo. In other analyses, the relationships between reported sleep quality and several standard measures of fibromyalgia were evaluated. According to each of the three different assessments of sleep quality used in BESTFIT, improvement in patient-reported sleep quality was found to significantly correlate with improvement in pain as well as broader measures of fibromyalgia symptoms and impact. These findings from BESTFIT may support the hypothesis that improving sleep quality facilitates pain improvement over time, and is consistent with the growing recognition of a reciprocal relationship between sleep and chronic, widespread pain. Nonrestorative sleep has been linked to altered processes in the brain that are thought to be responsible for certain fibromyalgia symptoms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use